Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZIMMER BIOMET HOLDINGS, INC.

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zimmer Biomet : Swings to 2Q Loss Amid Elective-Surgery Decline

08/04/2020 | 07:13am EDT

By Matt Grossman

 

Zimmer Biomet Holdings Inc. on Tuesday swung to a second-quarter loss as revenue declined amid lower volumes of elective surgeries during the Covid-19 pandemic.

However, the company reported a small per-share adjusted profit, beating analysts' expectations for an adjusted loss.

The Warsaw, Ind.-based company, which makes orthopedic medical products, recorded a second-quarter loss of $206.6 million, or $1 a share, compared with a profit of $133.7 million, or 65 cents a share, in the same three-month period a year earlier.

On an adjusted basis, Zimmer Biomet earned a profit of 5 cents a share. Analysts had expected an adjusted loss of 71 cents a share, according to FactSet.

Revenue in the latest quarter declined to $1.23 billion, from $1.99 billion in the year-earlier period. Analysts had forecast revenue of $921 million.

Zimmer Biomet declined to offer forward-looking guidance. Despite a recovery in elective-surgery volumes, the pandemic's continued impact is uncertain, it said.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

All news about ZIMMER BIOMET HOLDINGS, INC.
07/15BACTIGUARD : Interim report for Q2 2021
AQ
07/06ZIMMER BIOMET : Announces Webcast and Conference Call of Second Quarter 2021 Fin..
PR
07/01ZIMMER BIOMET : Makes Milestone Payment to Sweden's Bactiguard After Trauma Impl..
MT
06/30BACTIGUARD : receives payment from Zimmer Biomet
AQ
06/25ZIMMER BIOMET HOLDINGS, INC. : Ex-dividend day for
FA
06/15BACTIGUARD : coated Zimmer Biomet trauma implants for infection prevention launc..
AQ
06/10Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2021, Payabl..
CI
06/07Zimmer Biomet Holdings Names Chief Science, Technology and Innovation Officer
MT
06/07Zimmer Biomet Announces New Appointments to Executive Leadership Team
CI
06/03Zimmer Biomet Holdings Seeks Acquisitions
CI
More news
Financials (USD)
Sales 2021 8 115 M - -
Net income 2021 1 063 M - -
Net Debt 2021 6 229 M - -
P/E ratio 2021 32,1x
Yield 2021 0,59%
Capitalization 33 985 M 33 985 M -
EV / Sales 2021 4,96x
EV / Sales 2022 4,53x
Nbr of Employees 20 000
Free-Float 66,7%
Chart ZIMMER BIOMET HOLDINGS, INC.
Duration : Period :
Zimmer Biomet Holdings, Inc. Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 163,01 $
Average target price 190,46 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Nitin Goyal Chief Science, Technology & Innovation Officer
Ivan Tornos Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZIMMER BIOMET HOLDINGS, INC.5.79%34 070
ABBOTT LABORATORIES10.49%214 960
MEDTRONIC PLC12.10%176 468
BECTON, DICKINSON AND COMPANY2.21%74 377
ALIGN TECHNOLOGY, INC.30.21%55 063
SARTORIUS STEDIM BIOTECH65.28%52 629